Sensei Biotherapeutics, Inc. (SNSE)
NASDAQ: SNSE · Real-Time Price · USD
8.75
-0.31 (-3.47%)
At close: Feb 4, 2026, 4:00 PM EST
8.74
-0.01 (-0.11%)
After-hours: Feb 4, 2026, 6:53 PM EST
Sensei Biotherapeutics Employees
As of December 31, 2024, Sensei Biotherapeutics had 15 total employees, including 14 full-time and 1 part-time employees. The number of employees decreased by 13 or -46.43% compared to the previous year.
Employees
15
Change (1Y)
-13
Growth (1Y)
-46.43%
Revenue / Employee
n/a
Profits / Employee
-$1,609,200
Market Cap
11.03M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 15 | -13 | -46.43% | 14 | 1 |
| Dec 31, 2023 | 28 | 0 | - | 27 | 1 |
| Dec 31, 2022 | 28 | -28 | -50.00% | 28 | 0 |
| Dec 31, 2021 | 56 | 24 | 75.00% | 56 | 0 |
| Dec 31, 2020 | 32 | - | - | 30 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Bolt Biotherapeutics | 40 |
| Curis | 34 |
| BioLineRx | 28 |
| Longeveron | 25 |
| Imunon | 25 |
| BioCardia | 20 |
| Moleculin Biotech | 17 |
| Soligenix | 16 |
SNSE News
- 4 weeks ago - Egle Therapeutics Appoints John Celebi as Chief Executive Officer - GlobeNewsWire
- 2 months ago - Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value - GlobeNewsWire
- 3 months ago - Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025 - GlobeNewsWire
- 4 months ago - Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025 - GlobeNewsWire
- 5 months ago - Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 6 months ago - Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025 - GlobeNewsWire